

Evaluating a Novel, Portable, Self-Administrable Device (“Beacon”) that Measures Critical Flicker Frequency as a Test for Hepatic Encephalopathy

Philip Vutien^{1,2*}, Richard Li^{3*}, Ravi Karkar^{4,3}, Sean A. Munson⁵, James Fogarty³, Kara Walter¹, Michael Yacoub¹, George N. Ioannou^{1,2}

*These authors contributed equally to this manuscript.

¹University of Washington, Division of Gastroenterology and Hepatology, Seattle, WA, USA

²Department of Medicine Veterans Affairs Puget Sound Healthcare System and University of Washington, Seattle, WA, USA

³Paul G. Allen School of Computer Science & Engineering, University of Washington, Seattle, WA, USA

⁴Manning College of Information and Computer Sciences, University of Massachusetts Amherst, Amherst, MA, USA

⁵Human Centered Design & Engineering, University of Washington, Seattle, WA, USA

Guarantors of the article:

George Ioannou, MD, MS, FAASLD
Veterans Affairs Puget Sound Health Care System
Gastroenterology
S-111-Gastro
1660 S. Columbian Way
Seattle, WA 98108
Tel 206-277-3136
Fax 206-764-2232
georgei@medicine.washington.edu

Philip Vutien, MD, MS
University of Washington
Division of Gastroenterology and Hepatology
1959 NE Pacific Street, Box 356175
Seattle, WA 98195-6175
pvutien@uw.edu

Declaration of funding interests:

This study was funded in part by NIH/NIDDK award number R21DK117431 and by NIH/NLM award number R01LM012810.

The Beacon device is covered under patent number US 2021/0068733, published on March 11th 2021. The investigators own the data, performed all statistical analysis, and prepared the entire manuscript independently.

Author e-mails

- 1) Philip Vutien: pvutien@uw.edu
- 2) Richard Li: lichard@cs.washington.edu
- 3) Ravi Karkar: rkarkar@umass.edu
- 4) Sean A. Munson: smunson@uw.edu
- 5) James Fogarty: jfogarty@cs.washington.edu
- 6) Michael Yacoub: yacoum@medicine.washington.edu
- 7) Kara Walter: karitand@gmail.com
- 8) George N. Ioannou: george.ioannou@va.gov

Authorship Contributions:

- 1) Philip Vutien: Study concept and design, analysis and interpretation of data, drafting and critical review of the manuscript
- 2) Richard Li: Study concept and design, analysis and interpretation of data, drafting and critical review of the manuscript
- 3) Ravi Karkar: Study concept and design, analysis and interpretation of data, critical review of the manuscript
- 4) Sean A. Munson: Study concept and design, analysis and interpretation of data, critical review of the manuscript
- 5) James Fogarty: Study concept and design, analysis and interpretation of data, critical review of the manuscript
- 6) Kara Walter: Study concept and design, acquisition of data, critical review of the manuscript
- 7) Michael Yacoub: acquisition of data, critical review of the manuscript
- 8) George N. Ioannou: Study concept and design, analysis and interpretation of data, drafting and critical review of the manuscript

Keywords: Flicker fusion, covert encephalopathy, Beacon-App, Beacon, home testing

Abbreviations:

CFF: Critical flicker frequency
Lafayette-FFS: Lafayette Flicker Fusion System
MOL-D: Method-of-limits descending
MHE: Minimal hepatic encephalopathy
CI: Confidence Interval
MELD: Model for end-stage liver disease
CTP: Child-Turcotte-Pugh

Conflicts of interest: All authors disclose no conflicts of interests in relation to this manuscript.

Title count: 18 words, 144 characters

Manuscript word count: 998 words

Abstract word count: 100 (limit 100)

Tables: 1

Figures: 2

Abstract

Background: We compared critical flicker frequency (CFF) thresholds obtained using a novel, portable device “Beacon” with thresholds from the commercially available Lafayette Flicker Fusion System (Lafayette-FFS) in patients with cirrhosis.

Methods: 153 participants with chronic liver disease underwent CFF testing using Beacon and Lafayette-FFS with a method-of-limits and/or forced-choice protocol.

Results: Beacon demonstrated excellent test-retest reliability (intraclass correlation 0.91-0.97) and good correlation with the Lafayette-FFS values (intraclass correlation 0.77-0.84). Forced-choice CFFs were on average 4.1 Hz higher than MOL-D CFFs.

Conclusions: Beacon can be self-administered by patients with chronic liver disease and cirrhosis to measure CFF, a validated screening test for minimal hepatic encephalopathy.

Introduction

The critical flicker frequency (CFF) is a well-studied neurophysiologic screening test for minimal hepatic encephalopathy (MHE)(1-4). Currently available devices that measure CFF, such as the Flicker Fusion System (Lafayette-FFS; Lafayette Instrument Company, Lafayette, IN), are large, expensive, and not designed for at-home use(5). To address this limitation, we developed Beacon, a novel, portable device that measures CFF and is administered by a smartphone app(6). Beacon has not yet been evaluated in patients with chronic liver disease or cirrhosis. In addition, CFF is typically measured using a method-of-limits descending (MOL-D) protocol, which is prone to a response bias due to observer familiarity with testing. The aims of this study were to:

- i) Determine if patients with chronic liver disease can self-measure CFF using Beacon.
- ii) Evaluate the level of agreement for measures obtained by Beacon and the Lafayette-FFS.
- iii) Compare the frequencies obtained from a forced-choice protocol to those obtained from a MOL-D protocol.

Methods

Study participants and testing

We recruited participants from the hepatology clinics of the University of Washington between 1/2019-12/2021. Study participants completed CFF testing with Beacon (**Figure 1a-b**) and/or the Lafayette-FFS (**Figure 1c**) using a MOL-D and/or a forced-choice protocol (**Supplementary methods and supplementary figure 1**).

Statistical Analysis

We calculated the intraclass correlation to assess degree of correlation between Beacon and the Lafayette-FFS. The intraclass correlation assesses the degree of correlation between two scores but allows for a systematic difference between the two scores (e.g., $score1 = score2 + c$, where c is a constant). Difference plots were also generated to display differences between devices and protocols. All statistical analyses were run in R version 1.4.1717.

Results

Among the 153 study participants, 108 had cirrhosis and 45 had chronic liver disease without cirrhosis (**Table 1**). The test-retest intraclass correlation of Beacon was 0.95 (95% CI 0.91-0.97) for the MOL-D protocol and 0.92 (95% CI 0.88-0.95) for the forced-choice protocol (**Figure 2a-b**).

Correlation between CFF thresholds determined by Beacon and Lafayette-FFS

The mean values were similar (39.2 Hz for Beacon vs. 39.3 Hz for Lafayette-FFS) for MOL-D derived CFF thresholds and the intraclass correlation between the two devices was 0.77 (95% 0.67 – 0.85)

(Supplementary table 1). Among those with cirrhosis (n = 60), the mean CFF threshold for the two devices were similar (38.1 Hz for Beacon vs. 37.9 Hz for Lafayette-FFS vs., mean difference 0.4 Hz) and the intraclass correlation was 0.76 (95% CI 0.63-0.85).

CFF Thresholds obtained using the forced-choice protocol were higher than those obtained using the MOL-D protocol

The mean threshold obtained using the forced-choice protocol was higher (44.9 Hz for the forced-choice vs. 40.8 Hz for MOL-D, mean difference 4.1 Hz) **(Supplementary table 2)** and intraclass correlation for the two protocols was 0.73 (95% CI 0.61-0.82).

Beacon-derived CFF thresholds are lower for those with cirrhosis

Compared to participants without cirrhosis, those with cirrhosis had lower MOL-D derived thresholds (Beacon: 38.1 vs. 42 Hz, $p < 0.001$) **(Table 1, Figure 2)**. In a subgroup analysis of participants with cirrhosis, there was no significant difference in thresholds between those without prior overt encephalopathy (mean 39.0 Hz for MOL-D, mean 43.1 Hz for forced-choice) vs. those with prior overt encephalopathy (mean 37.4 Hz for MOL-D, 43.3 Hz for forced-choice) **(Figure 2)**.

Beacon-derived CFF thresholds are lower with increasing age

Among those with cirrhosis, for each decade increase in age CFF thresholds decreased an average of 1.3 Hz (95% CI 0.7 to 1.9 Hz) for the MOL-D protocol and 2.3 Hz (95% CI 1.3 to 3.3 Hz) for the forced-choice protocol **(Supplementary figure 2 and 3)**.

Discussion

Patients with chronic liver disease and cirrhosis were able to self-administer Beacon to measure CFF, a validated screening test for MHE (1, 2, 4, 7). Beacon-derived CFF thresholds were reliable and demonstrated good correlation with those obtained using the commercially available Lafayette-FFS device.

Beacon offers a portable option for CFF testing that can complement available MHE screening tests, such as the Stroop test, inhibitory control test, and electroencephalogram. One widely used test is the

smartphone application EncephalApp, which administers the Stroop test, a psychometric test of cognitive flexibility and response inhibition(8-10). However, as a psychometric test, performance can be confounded by effort, education, and other social determinants of health. Beacon, as a *neurophysiologic test* that measures CFF, is unlikely to be affected by these factors, although it is clearly affected by age (indicating that age-adjusted thresholds for MHE are likely required) and by the intensity of the light source. As such, CFF testing with Beacon can serve as an alternative or complementary at-home screening test that can improve HE screening rates, which are currently low(11, 12). We hope to make Beacon available to patients, clinical providers, and other investigators.

Prior studies evaluating CFF as a screening test for MHE have generally used a method-of-limits protocol, which is prone to a response bias from test familiarity(13). We piloted an alternative forced-choice protocol(13). We found that the forced-choice protocol was reliable, however, the average completion time (> 5 minutes) may be inconvenient for routine at-home screening of MHE.

We note potential study limitations. First, prior studies in patients with liver disease have used the Hepatonorm Analyzer (NevoLAB, Maierhofen, Germany) to measure CFF. However, this device was not available for purchase in the United States. We instead used the commercially available Lafayette-FFS, which has been used for CFF measurement for other disease processes (14, 15). Second, we did not evaluate for the presence of MHE using other measures such as psychometric testing. Finally, this study was also not designed to assess risk of clinical outcomes associated with baseline CFF values. Additional studies are planned to evaluate if at-home CFF measurements using Beacon are associated with the development of clinical outcomes including overt hepatic encephalopathy.

Conclusion

Beacon is a reliable, portable, and self-administrable device that measures CFF as a screening test for MHE. Further studies with long-term follow-up are needed to study the impact of home-based, self-monitoring of CFF using Beacon on clinical outcomes, including overt hepatic encephalopathy, hospitalizations, and mortality.


FIGURE LEGENDS

Figure 1: Devices used in this study to measure critical flicker frequency.

1a) Beacon light source. The Beacon system consists of two components: the light stimulus source (A) with wireless controller and battery base (B) (overall dimensions: 8.9 cm x 30 cm), and an application running on a smartphone for user input and to record results (C).



1b) Smartphone application. The light stimulus source is controlled by a companion application running on a smartphone connected via Bluetooth. Users are presented with instructions (left); an interface for inputting when they see the light flicker, by pressing anywhere on the full screen "Press Here" button (middle); and their CFF measurement in Hz (right).




1c) The Lafayette Flicker Fusion System. There are three components: a viewing chamber with the light stimulus, a controller, and a software program to record results.




Figure 2a and 2b. Beacon test-retest characteristics (2a-2b) and output by cirrhosis and prior overt hepatic encephalopathy (2c-2d).


2a) Beacon demonstrated excellent test-retest reliability using the MOL-D protocol (ICC 0.95, 95% CI: 0.91-0.97).



2b) Beacon demonstrated excellent test-retest reliability using the forced-choice protocol (ICC 0.92, 95% CI: 0.88 – 0.95).



2c-2d) Compared to participants without cirrhosis, those with cirrhosis had lower MOL-D (Figure 2c) derived and forced-choice (Figure 2d) derived thresholds. Among patients with cirrhosis, there was no significant difference in thresholds between those without a history of overt encephalopathy (mean 39.0 Hz for MOL-D, mean 43.1 Hz for forced-choice) vs. those without prior overt encephalopathy (mean 37.4 Hz for MOL-D, 43.3 Hz for forced-choice).






Table 1. Baseline characteristics of the study participants who underwent in-clinic testing with the Lafayette-FFS and Beacon devices

Baseline characteristics	All Participants (N=153)	Participants with cirrhosis (n = 108)	Participants without cirrhosis (n = 45)
Age, years (mean \pm SD)	53.4 \pm 13.8	56.9 \pm 12.5	44.9 \pm 13.1
Male	89 (58.2%)	66 (61.1%)	22 (48.9%)
Race/ethnicity			
White, non-Hispanic	128 (83.7%)	92 (85.2%)	36 (80%)
Black, non-Hispanic	5 (3.3%)	3 (2.8%)	2 (4.4%)
Asian	8 (5.2%)	2 (1.9%)	6 (13.3%)
Hispanic or Latino	6 (3.9%)	5 (4.6%)	1 (2.2%)
Other	6 (3.9%)	6 (5.6%)	0 (0%)
Underlying liver disease			
Hepatitis C	29 (19.0%)	26 (24.1%)	3 (6.7%)
Hepatitis B	11 (7.2%)	1 (0.9%)	10 (22.2%)
Non-alcoholic fatty liver disease or cryptogenic	33 (21.6%)	33 (30.6%)	7 (15.6%)
Alcohol-related	27 (17.6%)	25 (23.1%)	2 (4.4%)
Autoimmune, PBC, PSC	32 (20.9%)	19 (17.6%)	13 (28.9%)
Other liver disease	14 (9.2%)	4 (3.7%)	10 (22.2%)
MELD score (mean \pm SD)	-	14.5 \pm 6.3	-
CTP Class			
A	-	47 (43.5%)	-
B	-	44 (40.7%)	-
C	-	17 (15.7%)	-
Non-bleeding esophageal varices	-	68 (63.0%)	-
Bleeding esophageal varices	-	28 (25.9%)	-
History of TIPS	-	17 (15.7%)	-
Prior history of hepatic encephalopathy	-	49 (45.4%)	-
Medication use*			
Diuretic use	-	53 (49.1%)	-
Beta Blocker	-	27 (25%)	-
Lactulose	-	42 (38.9%)	-
Rifaximin	-	28 (25.9%)	-
Critical Flicker Frequency (Hz, mean \pm SD)			
Lafayette-FFS: MOL-D	39.3 \pm 6.1	37.9 \pm 5.9	43.1 \pm 5.0
Beacon: MOL-D	39.2 \pm 4.4	38.1 \pm 4.2	42.0 \pm 3.7
Beacon: forced-choice	44.7 \pm 5.4	43.0 \pm 6.8	46.9 \pm 4.8

MELD: Model for end stage liver disease, CTP: Child-Turcotte-Pugh, TIPS: transjugular intrahepatic portosystemic shunt, PBC: Primary biliary cholangitis, PSC: Primary sclerosing cholangitis

Supplementary-<http://links.lww.com/AJG/C885>

References

1. Barone M, Shahini E, Iannone A, et al. Critical flicker frequency test predicts overt hepatic encephalopathy and survival in patients with liver cirrhosis. *Dig Liver Dis* 2018;50:496-500.
2. Kircheis G, Bode JG, Hilger N, et al. Diagnostic and prognostic values of critical flicker frequency determination as new diagnostic tool for objective HE evaluation in patients undergoing TIPS implantation. *Eur J Gastroenterol Hepatol* 2009;21:1383-94.
3. Kircheis G, Hilger N, Haussinger D. Value of critical flicker frequency and psychometric hepatic encephalopathy score in diagnosis of low-grade hepatic encephalopathy. *Gastroenterology* 2014;146:961-9.
4. Torlot FJ, McPhail MJ, Taylor-Robinson SD. Meta-analysis: The diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy. *Aliment Pharmacol Ther* 2013;37:527-36.
5. Instruments L. Flicker Fusion System. 2021 [cited September 28, 2021]; Available from: <https://lafayetteevaluation.com/products/flicker-fusion>
6. Karkar R, Kocielnik R, Zhang X, et al. Beacon: Designing a Portable Device for Self-Administering a Measure of Critical Flicker Frequency. *Proceedings of the ACM on Interactive, Mobile, Wearable and Ubiquitous Technologies* 2018;2:1-27.
7. Ampuero J, Simon M, Montoliu C, et al. Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis. *Gastroenterology* 2015;149:1483-9.
8. Bajaj JS, Heuman DM, Wade JB, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. *Gastroenterology* 2011;140:478-487 e1.
9. Allampati S, Duarte-Rojo A, Thacker LR, et al. Diagnosis of Minimal Hepatic Encephalopathy Using Stroop EncephalApp: A Multicenter US-Based, Norm-Based Study. *Am J Gastroenterol* 2016;111:78-86.
10. Acharya C, Wade JB, Fagan A, et al. Overt hepatic encephalopathy impairs learning on the EncephalApp stroop which is reversible after liver transplantation. *Liver Transpl* 2017;23:1396-1403.

11. Bajaj JS. Diagnosing minimal hepatic encephalopathy: from the ivory tower to the real world. *Gastroenterology* 2015;149:1330-3.
12. Bajaj JS, Etemadian A, Hafeezullah M, et al. Testing for minimal hepatic encephalopathy in the United States: An AASLD survey. *Hepatology* 2007;45:833-4.
13. Eisen-Enosh A, Farah N, Burgansky-Eliash Z, et al. Evaluation of Critical Flicker-Fusion Frequency Measurement Methods for the Investigation of Visual Temporal Resolution. *Sci Rep* 2017;7:15621.
14. de Asis Fernandez F, Gonzalez-Mohino F, Gonzalez-Rave JM. Assessment of sensory sensitivity through critical flicker fusion frequency thresholds after a maximum voluntary apnoea. *Diving Hyperb Med* 2019;49:186-191.
15. Sanchez-Sanchez J, Felipe JL, Hernandez-Martin A, et al. Influence of the artificial turf certification on physical performance and muscle damage in football players (QUALTURF PROJECT). *Sci Rep* 2021;11:8625.